thought leadership
Webinar: After the midterms: What do the results mean for drug pricing, Medicare, and public health?
By Elif Alyanak; Lisa Grabowski; Matt Kazan | October 14, 2026
The midterms will change how Congress, the Trump administration, and state governments approach key drug pricing, Medicare, and public health programs. In a live webinar, Avalere Health’s federal and state policy experts explain where life sciences and health plans should focus their time and resources.
Less than 48 hours after polls close, Avalere Health Advisory experts will be on your screen, translating the results into sector-specific insights on key policies, programs, and markets. In a roundtable discussion, we will be looking at the future of:
- Medicare drug price negotiation
- PBM reform
- The 340B program
- Medicare Part D market stability
- Vaccines and public health
Join the webinar on November 5, 12-1PM ET
Register now to hear Avalere Health’s post-election perspective on the evolution of key drug pricing , Medicare, and public health programs over the next two years, and how you can prepare today.
Audience
This webinar is designed for life sciences and health plans teams that focus on:
-
-
- Federal/state policy or government affairs
- Market access
- Drug pricing
- Public health and vaccines
-
Learning objectives
Attendees will understand what issues policymakers are prioritizing for the next two years to inform their organization’s strategic planning.
Meet the speakers
Matt Kazan, SVP, Policy: Matt advises life sciences clients and health plans on IRA implementation and Medicare Part D and Medicare Advantage policy. Before joining Avalere Health, he spent more than a decade on staff for the US Senate Committee on Finance, most recently as Senior Health Policy Advisor.
Lisa Joldersma, Senior Advisor: Lisa is a seasoned strategic policy professional with 25 years of experience working at the intersection of state and federal health policy, advocacy, and law, and works closely with life sciences clients and health plans on federal and state health policy strategies that advance business priorities
Dr. Elif Alyanak, Managing Director: With expertise in health policy and vaccine research, Elif supports clients with evidence-based research and analysis that spans a variety of healthcare sectors and stakeholders.
Join the webinar
Join us on November 5 from 12-1 PM for a live webinar examining what the midterm election results will mean for the policies, programs, and markets most consequential to life sciences organizations and health plans.